agree with above comments;
- some costs cut out of US, good but is $2m enough?
- after a "successful" integration we are still looking at an EBITDA loss
- appears to be weaker sales revenue in immediate future
- silence on vaccine revenue trend into the remaining 2023, 2024 etc
- silent on cash at bank and capital management
wait and see from me.
DYOR
Ann: MDR undertakes strategic review, page-7
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
0.020(5.13%) |
Mkt cap ! $226.0M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 41.5¢ | 39.0¢ | $240.8K | 603.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.5¢ | 7692 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MDR (ASX) Chart |